Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well atezolizumab works alone or in combination with
tocilizumab in treating men with localized prostate cancer before radical prostatectomy.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by
prostate cancer and within the tumor microenvironment and shown to enhance prostate cancer
and disease progression. Treatment with an anti-IL-6 antibody such as tocilizumab may inhibit
cancer progression. Giving atezolizumab in combination with tocilizumab may work better in
treating prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Lawrence Fong University of California, San Francisco